Literature DB >> 15458596

Gilliatt-Sumner hand revisited: a 25-year experience.

Gabriel C Tender1, Ajith J Thomas, Najeeb Thomas, David G Kline.   

Abstract

OBJECTIVE: Thirty-three patients with true neurogenic thoracic outlet syndrome, or Gilliatt-Sumner hand, underwent surgical treatment at Louisiana State University during a 25-year period. This study retrospectively evaluated the outcome referable to pain and motor function in these patients.
METHODS: All patients had the typical Gilliatt-Sumner hand, secondary to compression of C8, T1, and/or lower trunk. Nineteen patients underwent an anterior supraclavicular approach, and 15 patients underwent a posterior subscapular approach to the brachial plexus. Nerve action potential recordings showed plexus involvement close to the spine, at the level of the junction of the spinal nerves to the lower trunk.
RESULTS: Pain, present in 22 patients, improved in 21. Mild motor deficit improved in 12 of 14 patients. Severe motor deficit improved partially in 14 of 20 patients.
CONCLUSION: The diagnosis of true neurogenic thoracic outlet syndrome provides a clear operative indication. Surgical decompression needs to involve the medial portion of the plexus, and especially the spinal nerves. An anterior supraclavicular approach is preferred in most cases. If there is a large cervical rib or there has been a prior anterior operation, then a posterior subscapular approach is indicated.

Entities:  

Mesh:

Year:  2004        PMID: 15458596     DOI: 10.1227/01.neu.0000137889.51323.0d

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  2 in total

1.  Supraclavicular approach for thoracic outlet syndrome.

Authors:  Julia K Terzis; Zinon T Kokkalis
Journal:  Hand (N Y)       Date:  2010-04-02

Review 2.  Use of Electroneuromyography in the Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Pauline Daley; Germain Pomares; Raphael Gross; Pierre Menu; Marc Dauty; Alban Fouasson-Chailloux
Journal:  J Clin Med       Date:  2022-09-02       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.